SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapeutic areas.
We are developing our lead product candidate, SCY-078, a novel and structurally distinct triterpenoid glucan synthase inhibitor. SCY-078 is in Phase 2 clinical development as an oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.
|Oct 5, 2017
SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017
|Sep 27, 2017
SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017
|Aug 31, 2017
SCYNEXIS to Present at Upcoming Investor Conferences